Sanofi Completes $3.68-Billion Acquisition of Principia Biopharma

News
Article

The acquisition will give Sanofi access to Principia’s Bruton tyrosine kinase inhibitors for its portfolio of next-generation transformative treatments for autoimmune diseases.

Sanofi announced on Sept. 28, 2020 that it has completed its acquisition of Principia Biopharma, a late-stage biopharmaceutical company located in San Francisco, CA, for approximately $3.68 billion.

The acquisition, first announced in Aug. 17, 2020, will give Sanofi access to Principia’s Bruton tyrosine kinase (BTK) inhibitors to add to its portfolio of next-generation transformative treatments for autoimmune diseases. The BTKs include BTK inhibitor ‘168, currently in a Phase IIb study for multiple sclerosis; rilzabrutinib, an oral BTK inhibitor currently in a Phase III program for moderate to severe pemphigus; and PRN473 topical, a topical agent currently in Phase I trials for immune-mediated diseases.

Sanofi and Principia had previously formed a collaboration in 2017 under which Principia granted Sanofi an exclusive, worldwide license to develop and commercialize BTK inhibitor ‘168 in multiple sclerosis and other central nervous system diseases.

Source: Sanofi​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Related Content
INTERPHEX 2025: Industry Initiates Interchangeable Single-Use Assembly Components in Response to COVID-19 Supply-Chain Disruption

INTERPHEX 2025: Industry Initiates Interchangeable Single-Use Assembly Components in Response to COVID-19 Supply-Chain Disruption

Patrick Lavery;Feliza Mirasol
April 3rd 2025
Article

Sitting down with the PharmTech Group at INTERPHEX 2025, Nicole Hunter, head of Global WMArchitect at WMFTS, explains the industry initiative around single-use assembly components resulting from supply disruptions caused by the COVID-19 pandemic.

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Question mark background | Image Credit: © Leigh-Prather - © Leigh Prather - stock.adobe.com

Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance

Susan J. Schniepp;Rona LeBlanc-Rivera, PhD
April 2nd 2025
Article

Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain

Jill Murphy
November 14th 2023
Podcast

In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.

TOP NEWS on grunge world map | Image Credit: © Sean K - © Sean K - stock.adobe.com

Martin A. Makary Becomes New FDA Commissioner

Susan Haigney
April 2nd 2025
Article

Martin A. Makary, confirmed by a bipartisan vote of the US Senate, has been sworn in as FDA’s new commissioner.

INTERPHEX 2025: How Functional Labeling Can Protect Parentals in Vials and Syringes

INTERPHEX 2025: How Functional Labeling Can Protect Parentals in Vials and Syringes

Patrick Lavery;Feliza Mirasol
April 1st 2025
Article

William Wainwright, business development manager at Iwata Label USA, discusses the practical security benefits of functional labels at INTERPHEX 2025.